Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

NAAS Rating: 5.03, Impact Factor: RJIF 5.98 | Free Publication Certificate
updates
NAAS Rating: 5.03 new
Vol. 8, Issue 4 (2019)

Colon targeted drug delivery systems: A boon for the treatment of inflammatory bowel disease

Author(s):
Laxmi Bhumarkar and Umesh Patil
Abstract:
Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the colon and small intestine. It is a spectrum of chronic, inflammatory conditions of the gastrointestinal (GI) tract. It is conventionally divided into two main subtypes: CD and UC. If inflammation affects the entire digestive tract called CD and if inflammation affects only in the large intestine called UC. Medications are used to treat symptoms caused by bacteria H. Pylori; highly acidic environment in bowel, foreign substances (Antigens) may be the direct cause of inflammation, changes in the endothelial blood vessel lining. It is an anti-inflammatory drug that works by lowering the inflammation in the colon. Sustained release, dosage forms are terms used to identify drug delivery systems that are designed to achieve a prolonged therapeutic effect by continuously releasing therapeutic agents over an extended period of time after administration of a single dose. The basic goal of the therapy is to achieve a steady state blood level that is therapeutically effective and nontoxic for an extended period of time. Systems provide medication over an extended period.
Pages: 549-557  |  118 Views  3 Downloads
How to cite this article:
Laxmi Bhumarkar, Umesh Patil. Colon targeted drug delivery systems: A boon for the treatment of inflammatory bowel disease. Pharma Innovation 2019;8(4):549-557.
The Pharma Innovation Journal